[ET Net News Agency, 27 September 2021] Akeso, Inc. (09926) said the company's
self-developed innovative drug candidate, IL-4R monoclonal antibody (research and
development code: AK120), was approved and agreed by the Food and Drug Administration of
the United States to initiate a global phase II clinical study for the treatment of
moderate-to-severe atopic dermatitis.
This is a multi-centre, randomized, double-blind, placebo-controlled, parallel, dosage
exploration phase II clinical trial to evaluate the efficacy and safety of AK120 in adult
subjects with moderate-to-severe atopic dermatitis.
AK120 is a novel drug targeting IL-4R of autoimmune treatment diseases independently
developed by the company. AK120 is intended to be used for the treatment of atopic
dermatitis, asthma and other allergic diseases. AK120 clinically treats allergic
autoimmune diseases by blocking the biological activities of dual cytokines IL-4 and
IL-13. (RC)